Phase I Study of Rapid Alternation of Sunitinib and Regorafenib for the Treatment of Tyrosine Kinase Inhibitor Refractory Gastrointestinal Stromal Tumors.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Polyclonal emergence of KIT secondary mutations is a main mechanism of imatinib progression in gastrointestinal stromal tumor (GIST). Approved KIT inhibitors sunitinib and regorafenib have complementary activity against KIT resistance mutations. Preclinical evidence suggests that rapid alternation of sunitinib and regorafenib broadens the spectrum of imatinib-resistant subclones targeted.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Clin. Cancer Res.

Title: Clinical cancer research : an official journal of the American Association for Cancer Research

Publisher: American Association for Cancer Research (AACR)

ISSN: 1078-0432

ISSN (Print): 1078-0432

Publication date (Electronic): Dec 15 2019

Volume: 25

Issue: 24

Affiliations

[1 ] Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. cserrano@vhio.net suzanne_george@dfci.harvard.edu.

[2 ] Department of Pathology, Brigham and Women's Hospital/Harvard Medical School, Boston, Massachusetts.

[3 ] Sarcoma Translational Research Laboratory, Vall d'Hebron Institute of Oncology; Department of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain.

[4 ] The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.

[5 ] Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.

[6 ] Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

[7 ] Ludwig Center for Cancer Research at Dana-Farber Cancer Institute and Harvard Medical School, Boston Massachusetts.

Article

Publisher Item ID: 1078-0432.CCR-19-2150

DOI: 10.1158/1078-0432.CCR-19-2150

PubMed ID: 31471313

SO-VID: 71b823b4-a5e8-4583-835b-738094781947

History

Data availability:

Comments

Comment on this article

scite_

Cited by 27

See all cited by